Goldline Pharmaceutical Ltd IPO
Pharmaceuticals
Price Band
₹41 – ₹43
Lot Size
3000
Minimum Bid Quantity
6000
Minimum Investment
₹258000
Issue Size
₹11.61Cr
Opens
2026-05-12
Closes
2026-05-14
Listing
19-05-2026
Subscription Status
Qualified Institutional Buyers
180.22 x
Non-Institutional Investor
1224.38 x
Retail Individual Investor
856.45 x
Total
769.61 x
IPO Details
Issue Type
FP
Face Value
₹10
Tick Size
1
ISIN
INE1CLW01015
Pre-Apply Available
No
Daily Bidding Time
10:00:00 - 17:00:00
About the Company
Goldline Pharmaceutical Limited is engaged in the marketing and distribution of pharmaceutical products under the “Goldline” brand. The company operates through five product segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness, catering to therapeutic areas including cardiology, diabetology, orthopaedics, paediatrics, gastroenterology, neurology, critical care, and oncology supportive care. Its products are manufactured through contractual arrangements with third-party manufacturers based on the company’s specifications, demand analysis, and market research. Goldline also provides material supply and procurement support services to hospitals and healthcare partners through promoter group entities involved in trading and supply chain operations. The company markets its products through a distribution network consisting of distributors, wholesalers, and retailers. As of March 31, 2025, Goldline maintained contractual arrangements with 15 manufacturers and seven distributors to support its supply chain and operations. Use of proceeds: This is a fresh issue of shares. Therefore, the net proceeds from the fresh issue will go to the company. They will be utilised for the following purposes: Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company — Rs 8.9 crore General corporate purposes
Pros
- • The company operates an asset-light business model by outsourcing manufacturing to third-party manufacturers instead of investing in its own manufacturing facilities. This allows the company to focus on marketing, product selection, and distribution while reducing capital expenditure on plant and machinery.
- • Goldline Pharmaceutical offers products across five different segments, namely Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. These product categories cater to multiple therapeutic areas such as cardiology, diabetology, orthopaedics, paediatrics, neurology, gastroenterology, critical care, and oncology supportive care.
- • The company claims to have established long-term relationships with third-party manufacturers and distributors to support its supply chain operations. As of March 31, 2025, the company maintained contractual arrangements with 15 manufacturers and seven distributors for product manufacturing and market distribution.
Cons
- • The company is dependent on third-party contract manufacturers for the production of its pharmaceutical products, as it does not own manufacturing facilities. As of March 31, 2025, the company had contractual arrangements with 15 manufacturers. Any adverse issues, such as supply delays, quality failures, contract non-renewals, or increases in manufacturing costs, could negatively impact the company’s operations and financial condition.
- • The company’s business is dependent on its ability to identify demand trends and successfully market new pharmaceutical products across its product portfolio. Goldline Pharma alone contributed Rs 13.52 crore (48.18%) of revenue in FY25, while Goldline Cardinal contributed Rs 6.91 crore (24.64%). Any failure to expand product offerings, respond to changing market demand, or maintain relationships with third-party manufacturers could adversely affect the company’s revenue and profitability.
- • The company is significantly dependent on a limited number of distributors for its revenue generation. Its largest distributor contributed Rs 10.87 crore (38.75%) in FY25, Rs 9.49 crore (40.28%) in FY24, and Rs 7.54 crore (38.01%) in FY23 to the company’s revenue from operations. Any loss of key distributors, non-renewal of agreements, or reduction in demand from these distributors could hurt the company’s business operations and financial condition.
Get real-time IPO alerts on WhatsApp
Opening reminders • Subscription updates • GMP alerts • Allotment results
Start WhatsApp Alerts